Survey Reveals Decline in Obesity as Americans Embrace Weight Loss Medications

Recently unveiled survey results indicate that as more individuals in the United States opt for pharmaceutical aids in weight reduction, the prevalence of obesity among adults is witnessing a downward trend.

Insights from Tuesday's publication demonstrate a gradual decrease in obesity rates among respondents, falling to 37% in 2025 from a peak of 39.9% in 2022. This conclusion is based on findings from three national online surveys involving 16,946 American adults conducted over the initial three quarters of 2025.

The document highlights that this approximately 2.9% reduction implies there are about 7.6 million fewer adults categorized as obese today compared to three years ago.

For the purposes of this survey, obesity is determined by the federal benchmark of a body mass index (BMI) of 30 or above.

The study additionally examined the rising use of GLP-1 medications, notably semaglutides, for weight management. Though these drugs are primarily prescribed for type 2 diabetes, currently reported by 13.8% of Gallup’s participants, they are increasingly utilized for shedding excess pounds.

In their initial measurement of GLP-1 consumption in early 2024, Gallup found that 5.8% of American adults were using these medications. This figure has since doubled to 12.4%, according to the latest data.

The report notes significant declines in obesity metrics across most age brackets since 2022, corresponding with the uptick in GLP-1 drug usage.

Noteworthy reductions in obesity are observed among two age demographics: those aged 40-49 and 50-64, both of which show the highest application rates of weight loss injectables.

The survey does acknowledge some limitations, specifically potential biases that might arise from self-reported data on weight and height. Nonetheless, Gallup assures that the consistency of their data collection methods preserves the integrity of the trend analysis.

Although GLP-1 usage for weight loss was not specifically tracked in 2022 or 2023, the overall trend of increasing use since FDA approval in 2021 has been corroborated by other data.

Even with a reduction in obesity levels, the United States still leads many Western nations in weight issues. Nonetheless, growing accessibility to treatments may sustain the observed decline in obesity rates, suggest the report’s authors.

As of September 2024, approximately 40% of American adults were classified as obese, marking the first instance in over a decade wherein national obesity figures have not increased, according to a federal health survey.